Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.
byBenzinga Newsdesk
August 15, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

OceanPal Inc. Announces Appointments Of Executive Officers And Time Charter Contract For m/v Salt Lake City, Gross Charter Rate Is $15,400 Per Day; Vasiliki Plousaki Appointed As New Chief Financial Officer, Effective As Of April 25, 2023

By Happy Mohamed
April 25, 9:47 AM
OceanPal Inc. (NASDAQ:OP) (the "Company"), a global shipping company specializing in the ownership of vessels, today announced that it has appointed Vasiliki Plousaki as the Company's new Chief Financial

OP